Next Article in Journal
COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety. Systematic Review and Meta-Analysis
Next Article in Special Issue
Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation
Previous Article in Journal
Expanding Protection Motivation Theory to Explain Willingness of COVID-19 Vaccination Uptake among Taiwanese University Students
Previous Article in Special Issue
Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection
Article

Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2

1
Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
2
Institute for Research on Cancer in Childhood and Adolescence, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
3
Immunology Laboratory, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico
*
Author to whom correspondence should be addressed.
Academic Editors: Ralph A. Tripp, Steven B. Bradfute and Scott Anthony
Vaccines 2021, 9(9), 1047; https://doi.org/10.3390/vaccines9091047
Received: 13 August 2021 / Revised: 12 September 2021 / Accepted: 17 September 2021 / Published: 20 September 2021
(This article belongs to the Collection COVID-19 Vaccines and Vaccination)
This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people (117 with prior COVID-19 and 229 without prior COVID-19) vaccinated with Ad5-nCoV were recruited. The percentage of neutralizing antibodies against SARS-CoV-2 (Surrogate Virus Neutralization Test) and antibodies against Ad5 (ADV-Ad5 IgG ELISA) were quantified pre and post-vaccination effects. The Ad5-nCoV vaccine induces higher neutralizing antibodies percentage in individuals with prior COVID-19 than those without prior COVID-19 (median [IQR]: 98% [97–98.1] vs. 72% [54–90], respectively; p < 0.0001). Furthermore, a natural infection (before vaccination) induces more neutralizing antibodies percentage than immunized individuals without prior COVID-19 (p < 0.01). No patient had vaccine-severe adverse effects. The age, antidepressant, and immunosuppressive treatments, reactogenicity, and history of COVID-19 are associated with impaired antibody production. The anti-Ad5 antibodies increased after 21 days of post-vaccination in all groups (p < 0.01). We recommend the application of a booster dose of Ad5-nCoV, especially for those individuals without previous COVID-19 infection. Finally, the induction of anti-Ad5 antibodies after vaccination should be considered if a booster with the same vaccine is planned. View Full-Text
Keywords: COVID-19; SARS-CoV-2; AD5-nCOV; neutralizing antibodies; vaccine; reactogenicity COVID-19; SARS-CoV-2; AD5-nCOV; neutralizing antibodies; vaccine; reactogenicity
Show Figures

Figure 1

MDPI and ACS Style

Hernández-Bello, J.; Morales-Núñez, J.J.; Machado-Sulbarán, A.C.; Díaz-Pérez, S.A.; Torres-Hernández, P.C.; Balcázar-Félix, P.; Gutiérrez-Brito, J.A.; Lomelí-Nieto, J.A.; Muñoz-Valle, J.F. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. Vaccines 2021, 9, 1047. https://doi.org/10.3390/vaccines9091047

AMA Style

Hernández-Bello J, Morales-Núñez JJ, Machado-Sulbarán AC, Díaz-Pérez SA, Torres-Hernández PC, Balcázar-Félix P, Gutiérrez-Brito JA, Lomelí-Nieto JA, Muñoz-Valle JF. Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. Vaccines. 2021; 9(9):1047. https://doi.org/10.3390/vaccines9091047

Chicago/Turabian Style

Hernández-Bello, Jorge, José J. Morales-Núñez, Andrea C. Machado-Sulbarán, Saúl A. Díaz-Pérez, Paola C. Torres-Hernández, Paulina Balcázar-Félix, Jesús A. Gutiérrez-Brito, José A. Lomelí-Nieto, and José F. Muñoz-Valle. 2021. "Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2" Vaccines 9, no. 9: 1047. https://doi.org/10.3390/vaccines9091047

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop